Stock listing
NASDAQ:OACC Oaktree Acquisition Corp. III Life Sciences Stock
Home listing (NASDAQ) of Oaktree Acquisition Corp. III Life Sciences
Follow Oaktree Acquisition Corp. III Life Sciences into a list and get an email when it puts out news.
Share price · NASDAQ:OACC
$10.71 USD -0.01 (-0.1%)
Close on Nov 20, 2026
- Day range
- $10.71 – $10.71 USDNov 20, 2026
- Volume
- 491 sharesNov 20, 2026
- Market cap
- $141.9M USDAt the close on Nov 20, 2026 · price × 13.25M shares outstanding
- 52-week range
- $10.50 – $10.93 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $356,502 USDMedian day 2,900 shares · 13 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:OACC · Home | $10.71 USD | -0.01 (-0.1%) | 491 | $10.71 | $10.71 | $10.71 | $10.72 | Close on Nov 20, 2026 |
| NASDAQ:OACCU | $10.76 USD | +0.01 (+0.1%) | — | $10.76 | $10.76 | $10.76 | $10.75 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OACC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.71 | -0.01 | -0.1% | $10.71 | $10.71 | $10.71 | 491 | |
| $10.72 | 0.00 | 0.0% | $10.72 | $10.72 | $10.72 | 220 | |
| $10.72 | +0.02 | +0.2% | $10.71 | $10.72 | $10.71 | 6,119 | |
| $10.70 | -0.02 | -0.2% | $10.70 | $10.70 | $10.70 | 825 | |
| $10.72 | 0.00 | 0.0% | $10.75 | $10.75 | $10.72 | 1,228 | |
| $10.72 | 0.00 | 0.0% | $10.72 | $10.72 | $10.72 | 208 | |
| $10.72 | +0.04 | +0.4% | $10.73 | $10.73 | $10.70 | 5,942 | |
| $10.68 | 0.00 | 0.0% | $10.68 | $10.68 | $10.68 | 43 | |
| $10.68 | -0.03 | -0.3% | $10.69 | $10.72 | $10.68 | 1,909 | |
| $10.71 | +0.02 | +0.2% | $10.70 | $10.71 | $10.69 | 5,100 | |
| $10.69 | 0.00 | 0.0% | $10.69 | $10.69 | $10.69 | 55 | |
| $10.69 | +0.03 | +0.3% | $10.67 | $10.69 | $10.66 | 14,600 | |
| $10.66 | +0.01 | +0.1% | $10.65 | $10.67 | $10.65 | 17,600 | |
| $10.65 | -0.05 | -0.5% | $10.65 | $10.66 | $10.65 | 25,700 | |
| $10.70 | +0.05 | +0.5% | $10.71 | $10.71 | $10.67 | 22,200 | |
| $10.65 | -0.28 | -2.6% | $10.72 | $10.73 | $10.65 | 7,100 | |
| $10.93 | +0.18 | +1.7% | $10.88 | $10.93 | $10.88 | 1,000 | |
| $10.75 | 0.00 | 0.0% | $10.75 | $10.75 | $10.75 | 10,900 | |
| $10.75 | 0.00 | 0.0% | $10.75 | $10.76 | $10.75 | 67,500 | |
| $10.75 | -0.01 | -0.1% | $10.75 | $10.76 | $10.75 | 228,700 | |
| $10.76 | 0.00 | 0.0% | $10.76 | $10.76 | $10.75 | 78,200 | |
| $10.76 | 0.00 | 0.0% | $10.76 | $10.76 | $10.76 | 0 | |
| $10.76 | 0.00 | 0.0% | $10.76 | $10.76 | $10.76 | 1,100 | |
| $10.76 | 0.00 | 0.0% | $10.76 | $10.76 | $10.74 | 280,300 | |
| $10.76 | -0.02 | -0.2% | $10.77 | $10.77 | $10.76 | 205,600 | |
| $10.78 | 0.00 | 0.0% | $10.78 | $10.78 | $10.78 | 73,054 | |
| $10.78 | 0.00 | 0.0% | $10.78 | $10.78 | $10.78 | 0 | |
| $10.78 | 0.00 | 0.0% | $10.78 | $10.78 | $10.78 | 0 | |
| $10.78 | 0.00 | 0.0% | $10.78 | $10.78 | $10.78 | 0 | |
| $10.78 | 0.00 | 0.0% | $10.78 | $10.78 | $10.78 | 2,900 | |
| $10.78 | +0.03 | +0.3% | $10.79 | $10.80 | $10.78 | 800 | |
| $10.75 | 0.00 | 0.0% | $10.80 | $10.80 | $10.75 | 6,300 | |
| $10.75 | +0.01 | +0.1% | $10.75 | $10.75 | $10.75 | 200 | |
| $10.74 | -0.031 | -0.3% | $10.74 | $10.75 | $10.72 | 100,700 | |
| $10.77 | 0.00 | 0.0% | $10.77 | $10.77 | $10.77 | 0 | |
| $10.77 | 0.00 | 0.0% | $10.77 | $10.77 | $10.77 | 0 | |
| $10.77 | 0.00 | 0.0% | $10.77 | $10.77 | $10.77 | 0 | |
| $10.77 | 0.00 | 0.0% | $10.77 | $10.77 | $10.77 | 0 | |
| $10.77 | +0.006 | +0.1% | $10.78 | $10.78 | $10.74 | 4,800 | |
| $10.77 | 0.00 | 0.0% | $10.77 | $10.77 | $10.77 | 0 | |
| $10.77 | +0.005 | 0.0% | $10.77 | $10.77 | $10.75 | 800 | |
| $10.76 | -0.04 | -0.4% | $10.75 | $10.78 | $10.74 | 5,500 | |
| $10.80 | 0.00 | 0.0% | $10.80 | $10.80 | $10.80 | 0 | |
| $10.80 | 0.00 | 0.0% | $10.80 | $10.80 | $10.78 | 140,600 | |
| $10.80 | 0.00 | 0.0% | $10.80 | $10.80 | $10.80 | 125,100 | |
| $10.80 | +0.04 | +0.4% | $10.80 | $10.80 | $10.77 | 97,600 | |
| $10.76 | 0.00 | 0.0% | $10.76 | $10.80 | $10.76 | 85,100 | |
| $10.76 | +0.02 | +0.2% | $10.74 | $10.78 | $10.74 | 55,400 | |
| $10.74 | -0.04 | -0.4% | $10.80 | $10.80 | $10.74 | 36,000 | |
| $10.78 | 0.00 | 0.0% | $10.78 | $10.78 | $10.78 | 0 | |
| $10.78 | 0.00 | 0.0% | $10.78 | $10.78 | $10.78 | 3,500 | |
| $10.78 | +0.04 | +0.4% | $10.78 | $10.78 | $10.78 | 400 | |
| $10.74 | 0.00 | 0.0% | $10.74 | $10.78 | $10.73 | 100,900 | |
| $10.74 | 0.00 | 0.0% | $10.74 | $10.74 | $10.74 | 0 | |
| $10.74 | 0.00 | 0.0% | $10.74 | $10.74 | $10.74 | 0 |
- Ticker
- NASDAQ:OACC
- Asset type
- Stock
- Sector
- Financials
- Industry
- Shell companies & SPACs
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · May 13, 2026
Oaktree Acquisition Corp. III Life Sciences 1Q 2026: Net income $1.39M, EPS $0.06— 10-Q Summary
Latest news
Oaktree Acquisition Corp. III Life Sciences 1Q 2026: Net income $1.39M, EPS $0.06— 10-Q Summary
May 13, 2026
Closed $10.64 (0.0%) on May 14, 2026
Oaktree Acquisition III Life Sciences reports $0 revenue, net income $7.29M
Mar 26, 2026
Closed $10.58 (-0.7%) on Mar 27, 2026
Oaktree Acquisition Corp. III Life Sciences on 6ix
- Sector
- Financials
- Industry
- Shell companies & SPACs
- News releases
- 2 in the last 12 months · 7 in all · newest May 13, 2026 · oldest 2025
Where Oaktree Acquisition Corp. III Life Sciences is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:OACC · Home listing · This page | NASDAQ | United States | USD |
| BOATS:OACC | BOATS | United States | USD |
| NASDAQ:OACCU | NASDAQ | United States | USD |
Valuation
P/E 32.7× against a median of 38.5×: 2nd lowest of 5 Shell companies & SPACs companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $140.7M USD
- P/E
- 32.7×
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.02
Shell companies & SPACs: the 10 companies nearest in size, of 284 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Oaktree Acquisition Corp. III Life Sciences · NASDAQ:OACC | US$141.9M | US$140.7M | 32.7× | n/a | n/a | n/a | n/a | n/a | 0.02 |
| TGE Value Creative Solutions Corp · NYSE:BEBE | US$151.3M | US$151.3M | 40.6× | n/a | n/a | n/a | n/a | n/a | n/a |
| Leapfrog Acquisition Corporation · NASDAQ:LFAC | US$150.4M | US$149.5M | n/a | n/a | n/a | n/a | n/a | n/a | -0.02 |
| Aperture AC · NASDAQ:APUR | US$149.1M | US$148.9M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| APEX Tech Acquisition Inc. · NYSE:TRAD | US$148.1M | US$148.1M | 202× | n/a | n/a | n/a | n/a | n/a | 0.02 |
| Andretti Acquisition Corp. II · NASDAQ:POLE | US$148.1M | US$147.9M | 23.1× | n/a | n/a | n/a | n/a | n/a | 0.01 |
| K2 Capital Acquisition Corporation · NASDAQ:KTWO | US$143.1M | US$142.3M | n/a | n/a | n/a | 275× | n/a | 0.0× | 0.03 |
| XFLH Capital Corporation · NYSE:XFLH | US$141.4M | US$141.1M | n/a | n/a | n/a | 340× | n/a | 0.0× | 0.05 |
| RF Acquisition Corp III · NASDAQ:RFAM | US$139.8M | US$138.9M | n/a | n/a | n/a | 235× | n/a | 0.0× | -0.01 |
| Chenghe Acquisition III Co. · NASDAQ:CHEC | US$134.9M | US$134.5M | 36.4× | n/a | n/a | n/a | n/a | n/a | 0.03 |
| Blue Water Acquisition Corp. IV · NYSE:BWIV | US$134.4M | US$134.4M | n/a | n/a | n/a | n/a | n/a | n/a | 0.00 |
| Median of the others | US$145.6M | US$145.1M | 38.5× | 275× | 0.0× | 0.02 |
Team and board
Officers
| Officer | Role |
|---|---|
| Zaid Pardesi | CEO and Director |
| George Martinez | CFO |
| Mathew Pendo | COO |
Board
| Director | Role |
|---|---|
| Aman Kumar | Chairman |
| Alvin Shih | Director |
| David Berry | Director |
| Paul Meister | Director |
| Zaid Pardesi | CEO and Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Nov 13, 2025 | 0.0% |
| Q2 2025 | Aug 12, 2025 | +0.6% |
| Q1 2025 | May 14, 2025 | −0.1% |
| Q3 2024 | Oct 4, 2024 |
IPO
A blank check company (SPAC). Priced at US$10.00 a unit on Oct 23, 2024.
- Price
- US$10.00 a unit
- Units offered
- 17,500,000 units
- Offering size
- US$175 million
- Underwriters' option
- Up to 2,625,000 more units
- Underwriters
- Jefferies, Citigroup, UBS Investment Bank · In the order on the cover
- Units delivered
- On or about Oct 25, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 7, 2024 |
| Filed publicly | Oct 4, 2024 |
| Amended once | Oct 18, 2024 |
| Shares registered with an exchange | Oct 23, 2024 |
| Declared effective by the SEC | Oct 23, 2024 |
| Final prospectus, with the price | Oct 24, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 24, 2024 |
| CERT · Exchange's certificate of listing | Oct 24, 2024 |
| EFFECT · Notice that a registration is effective | Oct 23, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 23, 2024 |
| CORRESP · Letter to the SEC | Oct 21, 2024 |
| CORRESP · Letter to the SEC | Oct 21, 2024 |
| CORRESP · Letter to the SEC | Oct 18, 2024 |
| S-1/A · Registration statement, amended | Oct 18, 2024 |
| UPLOAD · Letter from the SEC | Oct 18, 2024 |
| CORRESP · Letter to the SEC | Oct 4, 2024 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Oct 4, 2024 |
| UPLOAD · Letter from the SEC | Oct 1, 2024 |
| DRSLTR · Letter to the SEC with a draft | Sep 13, 2024 |
| DRS/A · Draft registration statement, amended | Sep 13, 2024 |
| UPLOAD · Letter from the SEC | Sep 5, 2024 |
| DRS · Draft registration statement | Aug 7, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 24, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 |
|---|---|
| Operating income | -1.20M |
| Net income | 7.29M |
Balance sheet
| Line | FY2025 |
|---|---|
| Cash and equivalents | 1.43M |
| Current assets | 1.55M |
| Total assets | 203.1M |
| Current liabilities | 1.30M |
| Total liabilities | 8.32M |
| Shareholders' equity | -6.77M |
Cash flow
| Line | FY2025 |
|---|---|
| Cash from operations | -422.1K |
| Cash from investing | 500.0K |
| Cash from financing | 0 |
| Change in cash | 77.9K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 26, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Oct 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 16, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 15, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Oct 2, 2026 | Meeting notice | SEC |
All 69 filings
Cap table
Built by 6ix from Oaktree Acquisition Corp. III Life Sciences’ releases
- Common shares
- 13,250,666
- Fully diluted
- 13,250,666
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 13,250,666 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 13,250,666 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John B. Frank Other companies: Daily Journal Corp. (S.C.) (Director · Since at least Oct 3, 2025); Chevron Corporation (Board Member · Since at least May 25, 2022) | Director · Oct 23, 2024 – Oct 23, 2024 · Past |
| David Berry Other companies: Averin Capital Acquisition Corp. (See Remarks, Director · Since at least Feb 18, 2026) | Director · Since at least Oct 17, 2025 |
| Aman Kumar | Director · Oct 23, 2024 – Oct 23, 2024 · Past |
| George Martinez | CFO · Since at least Oct 29, 2025 |
| Thomas Sweeney | Chief Financial Officer · Since at least Jun 3, 2025 |
Log in to ask 6ix AI your own questions about Oaktree Acquisition Corp. III Life Sciences.